• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » OptiKira launched by BioMotiv, UCSF, University of Washington

OptiKira launched by BioMotiv, UCSF, University of Washington

February 4, 2015
CenterWatch Staff

BioMotiv, a drug development accelerator associated with The Harrington Project, the University of California San Francisco (UCSF) and University of Washington, Seattle, have announced the formation of OptiKira, a platform company that will develop small molecule therapeutics that prevent cell death in pathologies caused by misfolded or unfolded proteins.

OptiKira is based on intellectual property exclusively licensed from UCSF and University of Washington.  

The project was initiated at UCSF and the University of Washington by scientific founders Scott Oakes, M.D., associate professor of pathology at UCSF; Feroz Papa, M.D., Ph.D., associate professor of medicine at UCSF; Bradley Backes, Ph.D., associate professor of medicine at UCSF; and Dustin Maly, Ph.D., associate professor in chemistry at University of Washington.

Oakes and Papa are members of the first class of Harrington Scholar-Innovators, an annual grant competition implemented by the Harrington Discovery Institute at University Hospitals in Cleveland, Ohio—part of The Harrington Project for Discovery and Development—that enables inventors' discoveries to be advanced towards preclinical proof-of-principle.  

Extensive research by the founders has helped define the biological pathway leading to progressive cell death which characterizes diseases such as retinitis pigmentosa, diabetes and amyotrophic lateral sclerosis (ALS). They have found the unfolded protein response (UPR), a mechanism by which the cell deals with functionally abnormal proteins, has an important housekeeping role in cell metabolism. However when overloaded, the "terminal UPR" results in the accumulation of excessive unfolded proteins and cellular death.

The team has synthesized inhibitors of IRE1a to prevent the activation of the terminal UPR, while not disrupting the housekeeping role of the enzyme. They have demonstrated that inhibitors of IRE1a, which they have named kinase-inhibiting RNase attenuators (KIRAs), protect cells from degeneration in preclinical models of retinitis pigmentosa and diabetes.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing